| dc.contributor.author |
Gaikwad, Anil Bhanudas |
|
| dc.date.accessioned |
2023-12-21T06:47:39Z |
|
| dc.date.available |
2023-12-21T06:47:39Z |
|
| dc.date.issued |
2018-06 |
|
| dc.identifier.uri |
https://www.sciencedirect.com/science/article/abs/pii/S1734114017304310 |
|
| dc.identifier.uri |
http://dspace.bits-pilani.ac.in:8080/xmlui/handle/123456789/13483 |
|
| dc.description.abstract |
Even after several novel therapeutic approaches, the number of people with diabetic nephropathy (DN) still continues to increase globally, this suggest to find novel therapeutic strategies to prevent it completely. Recent reports, are indicating the ubiquitin proteasome system alterations in DN. Recently, we also showed that, histone H2AK119 mono-ubiquitination (H2AK119-Ub) found to regulate Set7, a key epigenetic enzyme in the development of renal fibrosis under type 1 diabetic condition. Hence, we aimed to study the role of a known 20 s proteasome inhibitor Aspirin, on histone ubiquitination in the progression of DN. |
en_US |
| dc.language.iso |
en |
en_US |
| dc.publisher |
Elsevier |
en_US |
| dc.subject |
Pharmacy |
en_US |
| dc.subject |
Diabetic nephropathy (DN) |
en_US |
| dc.subject |
H2AK119 mono-ubiquitination |
en_US |
| dc.title |
Novel reno-protective mechanism of Aspirin involves H2AK119 monoubiquitination and Set7 in preventing type 1 diabetic nephropathy |
en_US |
| dc.type |
Article |
en_US |